Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 Patients with a minimum follow-up of 4 years

Acta Orthopaedica

Volumn 82, Issue 2, 2011, Pages 211-216

  Smeland, Sigbjørn ^a,b   Bruland, Øyvind S ^b,c   Hjorth, Lars ^d   Brosjö, Otte ^e   Bjerkehagen, Bodil ^c   Österlundh, Gustaf ^f   Jakobson, Åke ^e   Hall, Kirsten Sundby ^c   Monge, Odd R ^g   Björk, Olle ^e   Alvegaard, Thor A ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE;

ACUTE TOXICITY; ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOTOXICITY; CHILD; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INTOXICATION; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LEUKOPENIA; LIMB AMPUTATION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PREOPERATIVE CARE; ROTATIONPLASTY; SALVAGE THERAPY; SCHOOL CHILD; SEPTIC SHOCK; SEPTICEMIA; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; TYPHLITIS;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CISPLATIN; DOXORUBICIN; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; MALE; METHOTREXATE; NORWAY; OSTEOSARCOMA; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953806901     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2011.566141     Document Type: Article

References (24)

1. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
2. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico Rizzoli according to the istituto orotpedico Rizzoli/osteosarcoma-2 protocol: an update report. J Clin Oncol 2000; 18: 4016-27. (Pubitemid 32038393)
3. Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a-27-year experience in a single institution. J Surg Oncol 2007; 96: 118-23. (Pubitemid 47264814)
4. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinozoni F, Mercuri M, Monti C.Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 1993; 72: 3227-38.
5. Bielack S, Erttmann R, Kempf-Bielack B, Winkler K.Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the midnineties? Eur J Cancer 1996; 32: 1652-60. (Pubitemid 26306872)
6. Bielack S, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90. (Pubitemid 34111386)
7. Bruland O S, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33: 1725-31. (Pubitemid 28129196)
8. Enneking W F, Spanier S, Goodman M A, A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; (153): 106-20. (Pubitemid 11217753)
9. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, Del Prever AB, Fagioli F, Comandone A, Bacci G. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-5. (Pubitemid 46621907)
10. Ferrari, S, Smeland, S. Mercuri, M, Bertoni F, Longhi A, Ruggieri P, Alvegard T A, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-52. (Pubitemid 46211531)
11. Fuchs N, Bielack S S, Epler D, Bieling P, Delling G, Körholz D, Graf N, Heise U, Jürgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K.Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-9. (Pubitemid 28440449)
12. Huvos A G, Rosen G, Marcove C. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-8.
13. Kempf-Bielack B, Bielack S S, Jürgens H, Branscheid D, Berdel W E, Exner G U, Göbel U, Helmke K, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-68. (Pubitemid 46224233)
14. Lewis I J, Nooij M A, Whelan J, Sydes M R, Grimer R, Hogendoorn P C, Memon M A, Weeden S, Uscinska B M, van Glabbeke M, Kirkpatrick A, Hauben E I, Craft A W, Taminiau A H. Improvement in histologic response but not survival in osteosarcoma patietns treated with intensified chemotherapy: a randomized phase III trial of the European Ostesarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-8.
15. Link M P, Goorin A M, Miser A W, Green A A, Pratt C B, Belasco J B, Prichard J, Malpas J S, Baker A R, Kirkpatrick J A, et al.The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-16.
16. Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes M R, Butterfass. Baholul T, Calaminus G, Bernstein M. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2010; 152: 339-53.
17. Meyers P A, Schwartz C L, Krailo M, Kleinerman E S, Betcher D, Bernstein M L, Conrad E, Ferguson W, Gebhardt M, Goorin A M, Harris M B, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamdie and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004-11. (Pubitemid 46211380)
18. Rosen G, Caparros B, Huvos A G, Kosloff C, Nirenberg A, Cacavio A, Marcove R C, Lane J M, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30. (Pubitemid 12187826)
19. Rosen G, Marcove R C, Caparros B, Nirenberg A, Kosloff C, Huvos A G., Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-77.
20. Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Österlundh G, Jakobson Å, Hall K S, Monger O R, Björk O, Alvegaard T A. Scandinavian experience in classical osteosarcoma, results of the SSG XIV protocol. Acta Orthop (Suppl 334) 2009; 80: 60-6.
21. Smeland S, Müller C, Alvegaard T A, Wiklund T, Wiebe T, Björk O, Stenwig A E, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O R, Saeter G. Scandinavian Sarcoma Group Osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488-94. (Pubitemid 36173693)
22. Saeter G, Alvegård T A, Elomaa I, Stenwig A E, Holmström T, Solheim O P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
23. Saeter G, Høie J, Stenwig, A E, Johansson A K, Hannisdal E, Solheim O P. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995; 75: 1084-93.
24. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V Graf N, Russe W, Gruemayer E R, Ertelt W, Kotz R, Preusser R, Prindull G, Brandeis W, Landbecket G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 1988; 6: 329-37. (Pubitemid 18065939)